Jupiter Neurosciences, Inc. · NASDAQ:JUNS

Jupiter Neurosciences — Investor Presentation (February 2025)

18 slides from Jupiter Neurosciences's investor presentation, February 2025

  1. Slide 1: Our Solution: JOTROL (NASDAQ: JUNS)

    Inflammation in the brain damages and destroys brain cells, speeding aging and atrophy of your brain. Causing dementia, Alzheimer’s, Parkinson's and other degenerative brain diseases . Our Solution: JOTROL (NASDAQ: JUNS)

  2. Slide 2: Cautionary Note on Forward Looking Statements

    CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS This Presentation contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about

  3. Slide 3: The Jupiter Neurosciences Story

    The Jupiter Neurosciences Story Phase I Trial Breakthrough Pre- 2015 Clinical Data Financed by NIA/NIH, results showed ~9X In Parkinson's Disease, Founded with the goal of increased bioavailability, triggering Phase IIa trial developing a highly published in Journal of bioavailable resveratrol AD an

  4. Slide 4: Management

    Management Strong management team and advisors with extensive international experience and a track record for successfully building organizations that can take a product from inception to commercialization Christer ”Chris” Rosén Alexander Rosén Marshall Hayward, Ph.D Alison D. Silva Saleem Emasri, C

  5. Slide 5: Scientific Advisory Board

    Scientific Advisory Board Scientific Team comprising of world-renowned specialists in their respective fields, providing hands-on involvement and valuable assistance to JUNS Li-Huei Tsai, Ph.D. Raymond Turner, MD, Ph.D. Rudolph Tanzi, Ph.D. Charbel Moussa. MBBS Ph.D. Shaun Brothers, Ph.D., MBA Claes

  6. Slide 6: Resveratrol Mechanism of Action

    Resveratrol Mechanism of Action Pre-clinical animal studies have shown that resveratrol induces mitochondrial biogenesis and reduces inflammation MITOCHONDRIAL BIOGENESIS ANTI-INFLAMMATION ▪ Promotes mitochondrial biogenesis through ▪ Effectively scavenges and neutralizes free indirect AMPK and SIRT

  7. Slide 7: Resveratrol MOA and Applications

    Resveratrol MOA and Applications Resveratrol is a polyphenolic compound that exerts its effects through various mechanisms, including activation of the SIRT1 enzyme, modulation of inflammatory pathways, and regulation of cell signaling cascades. Antioxidant and DNA Repair Cardioprotective Potent ant

  8. Slide 8: The Resveratrol Story

    The Resveratrol Story ▪ Natural polyphenol supplement known for decades as a “miracle product”. ~14,000 scientific papers published. ▪ Severe GI side effects at therapeutically effective doses has prevented utilization and drug approvals (Turner & MCRI studies) ▪ JOTROL, developed by JUNS, the First

  9. Slide 9: Resveratrol (RSV) vs JOTROL

    Resveratrol (RSV) vs JOTROL RSV JOTROL Bioavailability Phase I study showed ~9 x higher bioavailability than Resveratrol at concentration maximum (Cmax) Intellectual Property Patents granted in USA, Europe, China, Hong Kong and Japan; JOTROL is protected through 2036 GI Tolerability at Efficacious D

  10. Slide 10: Neuroinflammation and Lack of Mitochondria are Major Causes for Many Diseases

    Neuroinflammation and Lack of Mitochondria are Major Causes for Many Diseases ALZHEIMER’S DISEASE PARKINSON’S DISEASE RARE DISEASES MITOCHONDRIAL HEALTHSPAN & MENTAL DISORDERS LONGEVITY DISORDERS DTC Opportunity 1 0 10

  11. Slide 11: Pipeline Development Strategy: One Phase I study enabling several indications

    Pipeline Development Strategy: One Phase I study enabling several indications starting directly in Phase II PRECLINICAL PHASE I PHASE II PHASE III Parkinson’s Disease (PD) Mucopolysaccharidosis (MPS) Type 1 Mitochondrial, encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) NEUROINFL

  12. Slide 12: MCI/Early-AD

    MCI/Early-AD “There is a collective understanding emerging: Alzheimer's will need to be attacked from several directions at once. Drugs like Aduhelm and Leqembi, which focus on the traditional amyloid target, will become only one of many strategies used to tackle the disease” stated by ADDF (Alzheim

  13. Slide 13: JOTROL is Neuroprotective

    JOTROL is Neuroprotective Motor Dysfunction in MPTP Model of Parkinson’s Disease CONCLUSION: JOTROLTM DEMONSTRATES BENEFICIAL NEUROLOGIC EFFECTS IN PD TRIGGERING A PHASE II A TRIAL 13

  14. Slide 14: MELAS

    MELAS Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes MELAS is the most common of the 12 acknowledged rare mitochondrial diseases. The commonality might lead to an accelerated approval process for the other diseases within this category. No existing treatment. Resveratrol

  15. Slide 15: Developments in South-East Asia

    Developments in South-East Asia ▪ Resveratrol is widely used and accepted in SE Asian markets ▪ Resveratrol currently approved as a Traditional Chinese Medicine (TCM) ▪ Business development contracts in place for product expansion ▪ Target is to get one or more out-licensing deals for China, Malaysi

  16. Slide 16: Direct To Consumer Approach

    Direct To Consumer Approach Following points will be evaluated before we execute, subject to separate financing ▪ Business plan to be developed focusing on Longevity and Aging ▪ Many functions can be out-sourced to existing successful DTC entities ▪ Start-up cost expected to be less than $3 Million

  17. Slide 17: Recent events → 2024/2025 Objectives

    Recent events → 2024/2025 Objectives Significant research and corporate accomplishments despite limited resources; positioned to execute in the second half of 2024 and into 2025 ▪ Phase I completed in healthy volunteers opens fast track to Phase II trials in multiple indications ▪ Preclinical study

  18. Slide 18: Contact

    Contact Jupiter Neurosciences, Inc. NASDAQ: JUNS 1001 North US HWY 1, Suite 504 Jupiter, FL 33477 +1 (561) 406-6154 [email protected] [email protected] www.jupiterneurosciences.com FOR INTENDED RECIPIENT US ONL 18

Jupiter Neurosciences — Investor Presentation (February 2025) on 6ix